Substance / Medication

Tamoxifen

Overview

Active Ingredient
tamoxifen
RxNorm CUI
10324

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

22 trials linked to this intervention

22
Total Trials
8
Recruiting
7
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Optical coherence tomography angiography measurements in tamoxifen associated retinopathy: a systematic review and meta-analysis.
Abdol Homayuni Mohammad Reza, Sadeghi Reza, Poshtdar Sepideh et al. · BMC Ophthalmol · 2025
PMID: 40597899Meta-AnalysisFull text (PMC)
Adjuvant treatment with tamoxifen for estrogen receptor-positive breast cancer and gynecological risks in premenopausal and perimenopausal women - a systematic review.
Plougmann Gislinge Julie Isabelle, Rubeck Petersen Kresten, Borgquist Signe et al. · Climacteric · 2025
PMID: 40539456Meta-Analysis
Tamoxifen and Fertility in Women with Breast Cancer: A Systematic Review on Reproductive Outcomes and Oncological Safety of Treatment Interruption.
Maiorano Mauro Francesco Pio, Cormio Gennaro, Loizzi Vera et al. · Int J Mol Sci · 2025
PMID: 40332441Meta-AnalysisFull text (PMC)
Targeting lipid metabolism to overcome tamoxifen resistance in breast cancer: Evaluating the synergistic therapeutic potential of quercetin.
Rifaat Radwa M, Kamel Marwa W, Sharaky Marwa et al. · Cancer Treat Res Commun · 2025
PMID: 40554412Meta-Analysis
The impact of tamoxifen on apolipoproteins and lipoprotein(a) levels: an updated meta-analysis of randomized controlled trials.
Jiang Yi, Zhang Lantian, Shen Dongyi et al. · Endocrine · 2025
PMID: 39776103Meta-Analysis
Unraveling the Impact of Drug Metabolism on Tamoxifen Response in Breast Cancer.
Schroth Werner, Mürdter Thomas E, Schwab Matthias · Cancer Epidemiol Biomarkers Prev · 2025
PMID: 39910985Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tamoxifen (substance)
SNOMED CT
373345002
UMLS CUI
C0039286
RxNorm CUI
10324

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
22
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.